Plasma insulin-like growth factor binding protein-3 proteolysis is increased in primary breast cancer

British Journal of Cancer

Volumn 85, Issue 1, 2001, Pages 74-77

  Helle, S I ^a   Geisler, S ^a   Aas, T ^a   Paulsen, T ^a   Holly, J M P ^b   Lonning, P E ^a  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b BRISTOL ROYAL INFIRMARY   (United Kingdom)

Author keywords

Insulin like growth factor binding protein 3; Insulin like growth factor I; Primary breast cancer; Proteolysis

Indexed keywords

SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER INVASION; CANCER STAGING; CARCINOMA IN SITU; CONTROLLED STUDY; FEMALE; HUMAN; METASTASIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PEPTIDE HYDROLASES; PROSPECTIVE STUDIES;

EID: 0035816253     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.2001.1860     Document Type: Article

References (20)

1. Insulin-like growth factor binding protein-3 proteolysis in children with insulin-dependent diabetes mellitus: A possible role for insulin in the regulation of IGFBP-3 protease activity
2. In vivo proteolysis of serum insulin-like growth factor (IGF) binding protein-3 results in increased availability of IGF to target cells
3. Insulin-like growth factor binding protein 3 is decreased in early-stage operable pre-menopausal breast cancer
4. Plasma insulin-like growth factor-I and prostate cancer risk: A prospective study
5. The differential regulation of the circulating levels of the insulin-ike growth factors and their binding proteins (IGFBP) 1,2 and 3 after elective abdominal surgery
6. The induction of a specific protease for insulin-like growth factor binding protein-3 in the circulation during severe illness
7. Effects of treatment with megestrol acetate, aminoglutethimide or formestane on insulin-like growth factor (IGF) I and II, IGF-binding proteins (IGFBPs) and IGFBP-3 protease status in patients with advanced breast cancer
8. Insulin-like growth factors I and II in healthy man. Estimation of half-lives and production rates
9. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer
10. Influence of treatment with tamoxifen and change in tumour burden on the 1GF-system in breast cancer patients
11. Regulation of insulin-like growth factor I receptor expression by the pure antiestrogen IC1 182780
12. Insulin-like growth factors and their binding proteins: Biological actions
13. Differential responsiveness of human breast cancer cell lines MCF-7 and T47D to growth factors and 17β-estradiol
14. Insulin-like growth factor receptors in human breast cancer and their relation to estradiol and progesterone receptors
15. Plasma Insulin-like growth factor-I (IGF-I) concentrations in human breast cancer
16. Correlation between apoptosis, tumorigenesis, and levels of insulin-like growth factor I receptors
17. Prognostic factors in metastatic breast cancer treated with combination chemotherapy
18. Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation
19. Type I IGF receptor and aquired tamoxifen resistance in oestrogen-responsive human breast cancer cells